Eisai Taps Novartis Oncology Firepower For Lenvima
This article was originally published in PharmAsia News
Executive Summary
Following the recent approval of Lenvima for kidney cancer in the US, Eisai has allied with major oncology player Novartis to help drive sales of the product in this market.
You may also be interested in...
New Indication For Lenvima In India Spawns Opportunities For Many?
Eisai’s lenvatinib is endorsed by an expert panel in India in combination with everolimus, for which multiple generic brands are available in addition to Novartis’ Afinitor. The Swiss multinational isn’t allying with Eisai in India at least for now.
Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting
During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.